Vertex Pharma Casgevy Exagamglogene Autotemcel: Positive Long-Term Data
Vertex Pharmaceuticals announced long-term data from global clinical trials of CASGEVY, a CRISPR/Cas9 gene-edited therapy, for severe sickle cellsickle...
Kite Pharma Yescarta Curative Potential in Relapsed Lymphoma
Kite, a Gilead Company, presented three analyses of Yescarta (axicabtagene ciloleucel) at the 66th American Society of Hematology (ASH)...
Bluebird Bio Lyfgenia Gene Therapy Shows Positive Long-Term Sickle Cell Disease Data
Bluebird bio announced updated data from its LYFGENIA gene therapy for sickle cellsickle cell disease (SCD) patients with a...
Innate Pharma & IFLI Announce $7.9M Investment for IPH6501 in Follicular Lymphoma
Innate Pharma and the Institute for Follicular Lymphoma (IFLI) have partnered to explore the potential of IPH6501, Innate’s anti-CD20...
Datopotamab Deruxtecan Shows Promising Activity in EGFR-Mutated NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate, showed promising results in a pooled analysis of two clinical trials...
Mirailab Launches NMN Supplements and Cosmetics in UAE
MIRAILAB BIOSCIENCE Inc. has launched its β-Nicotinamide Mononucleotide (β-NMN) supplement brand, “MIRAI LAB,” in the UAE. NMN, found naturally...
Veracyte Decipher Prostate Test Recommended in NCCN Guidelines
Veracyte’s Decipher Prostate Genomic Classifier is the only gene expression test included in the 2025 National Comprehensive Cancer Network...
Envision Trial Shows UGN-102’s Potential for LG-IR-NMIBC Treatment
UroGen Pharma announced positive Phase 3 ENVISION trial results for UGN-102, a mitomycin-based intravesical solution for recurrent low-grade intermediate-risk...
Maat Pharma Announces First US Patient Treated Under Expanded Access for Graft-Versus-Host Disease
MaaT Pharma has administered its investigational microbiome therapeutic, MaaT013, to the first patient in the United States under the...
Iliad Biotech’s Intranasal Pertussis Vaccine Gets Innovation Passport
ILiAD Biotechnologies’ intranasal pertussis vaccine, BPZE1, has received Innovation Passport designation from the UK Medicines & Healthcare Products Regulatory...